PepGen Inc. AI Stock Analysis
Want to see PEPG full AI Analyst Report?
PepGen Inc. (PEPG) AI Stock Analysis
PepGen Inc.
(NASDAQ:PEPG)
The score is primarily held down by weak financial performance (pre-revenue status, large losses, and ongoing cash burn), which dominates the risk profile. Technicals provide support via strong momentum and price above major moving averages, though overbought signals raise pullback risk. A positive corporate catalyst (encouraging Phase 2 results and tolerability) helps offset concerns, but regulatory overhang (partial clinical hold) and limited valuation support (negative P/E, no dividend) keep the overall score in the low-to-mid range.
PepGen Inc. (PEPG) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $301.98M
- Dividend Yield
- ―
- Average Volume (3M)
- 3.02M
- Price to Earnings (P/E)
- -3.5
- Beta (1Y)
- 1.40
- Revenue Growth
- ―
- EPS Growth
- 62.59%
- Country
- US
- Employees
- 56
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
PepGen Inc. Business Overview & Revenue Model
Company Description
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-co...
How the Company Makes Money
As a clinical-stage biotechnology company, PepGen Inc. does not have publicly available information indicating material recurring revenue from commercial product sales; therefore, detailed revenue model and key revenue streams are null. null
PepGen Inc. Earnings Call Summary
The earnings call highlighted significant progress in clinical trials and a strong financial position due to recent funding, as well as regulatory advancements such as FDA fast track designation. However, there were challenges with increased expenses and a notable net loss for the year. Despite these financial lowlights, the clinical and regulatory achievements present a strong positive outlook.
Q4-2023 Updates
Positive Updates
Negative Updates
Company Guidance
During the PepGen Q4 2023 earnings call, the company provided guidance on several key metrics and developments. They highlighted the initiation of clinical trials for their EDO cell-penetrating peptide platform targeting Duchenne Muscular Dystrophy (DMD) and myotonic dystrophy type 1 (DM1). PepGen's lead program, PGN-EDO51, aims to treat DMD with an exon 51-skipping approach, targeting approximately 13% of DMD patients in the U.S. and EU. They completed enrollment for cohort 1 in CONNECT1-EDO51 at a 5 mg per kg dose and anticipate escalating to 10 mg per kg pending safety reviews. The company expects preliminary data for the 5 mg per kg cohort by mid-2024, with projections suggesting high dystrophin production levels. For DM1, the FDA lifted a clinical hold on EDODM1, which received fast track designation. The FREEDOM-DM1 Phase I trial began dosing in December 2023, and PepGen aims to report preliminary data in the second half of 2024. Financially, PepGen reported a net loss of $19.5 million for Q4 and $78.6 million for the full year, with research and development expenses totaling $68.1 million in 2023. Following a stock offering in early 2024, they are positioned to fund operations into 2026.
PepGen Inc. Financial Statement Overview
Summary
Financial profile is weak due to being pre-revenue with materially negative profitability and persistent cash burn (TTM operating/free cash flow around -$63.3M). A partial offset is relatively low leverage and declining total debt, but ongoing losses are eroding equity and keep funding/burn-rate risk elevated.
Income Statement
12Very NegativeBalance Sheet
58NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1.38M | -1.40M | -1.50M | -1.18M | 0 | 0 |
| EBITDA | -71.30M | -88.21M | -89.09M | -77.37M | -64.91M | -27.10M |
| Net Income | -73.31M | -89.66M | -89.98M | -78.63M | -69.10M | -27.28M |
Balance Sheet | ||||||
| Total Assets | 127.78M | 173.91M | 150.88M | 143.05M | 217.44M | 143.64M |
| Cash, Cash Equivalents and Short-Term Investments | 104.81M | 148.46M | 120.19M | 110.41M | 181.75M | 132.90M |
| Total Debt | 15.61M | 17.00M | 18.66M | 20.10M | 24.53M | 0 |
| Total Liabilities | 24.71M | 26.46M | 32.26M | 34.63M | 37.81M | 10.55M |
| Stockholders Equity | 103.07M | 147.44M | 118.62M | 108.42M | 179.63M | 133.09M |
Cash Flow | ||||||
| Free Cash Flow | -63.28M | -81.90M | -82.87M | -71.60M | -63.02M | -23.10M |
| Operating Cash Flow | -63.25M | -81.64M | -82.37M | -69.00M | -59.27M | -22.60M |
| Investing Cash Flow | -58.76M | -15.23M | -37.67M | -32.00M | -3.75M | -500.00K |
| Financing Cash Flow | 1.20M | 107.98M | 88.75M | -189.00K | 112.19M | 147.66M |
PepGen Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PEPG, the sentiment is Positive. The current price of 4.36 is above the 20-day moving average (MA) of 2.98, above the 50-day MA of 2.80, and above the 200-day MA of 2.93, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 66.08 is Neutral, neither overbought nor oversold. The STOCH value of 63.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PEPG.
PepGen Inc. Risk Analysis
PepGen Inc. disclosed 96 risk factors in its most recent earnings report. PepGen Inc. reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksPepGen Inc. Peers Comparison
Overall Rating
LYEL53Neutral- PEPG51Neutral
LXEO50Neutral
EDIT43Neutral
RCKT42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| LYEL | 53Neutral | $384.52M | -0.91 | -107.62% | ― | -63.41% | 49.87% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| PEPG | 51Neutral | $349.08M | -3.54 | -58.18% | ― | ― | 62.59% |
| LXEO | 50Neutral | $238.88M | -2.50 | -41.85% | ― | ― | 64.51% |
| EDIT | 43Neutral | $330.29M | -3.51 | -130.43% | ― | 7.43% | 74.00% |
| RCKT | 42Neutral | $262.36M | -16.43 | -5.34% | ― | ― | 93.49% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PEPG | PepGen Inc. | 4.36 | -0.99 | -18.50% | |
| RCKT | Rocket Pharma | 2.30 | -0.74 | -24.34% | |
| EDIT | Editas Medicine Inc. | 2.17 | -0.41 | -15.89% | |
| LYEL | Lyell Immunopharma, Inc. | 14.30 | -3.12 | -17.91% | |
| LXEO | Lexeo Therapeutics, Inc. | 2.87 | -6.61 | -69.73% |
PepGen Inc. Corporate Events
PepGen Prices $125 Million Public Offering of Common Stock
NeutralOn November 10, 2026, PepGen launched a proposed $125.0 million public offering. On November 11, it entered an underwriting agreement and priced the offering at $5.00 per share for 25 million common shares, granting underwriters a 30-day option to pu...
PepGen Reports Positive FREEDOM2-DM1 Phase 2 Results
PositiveOn November 10, 2026, PepGen reported third-quarter financial results and topline results from the 10 mg/kg multiple ascending-dose cohort of its Phase 2 FREEDOM2-DM1 trial in patients with DM1. The cohort produced mean splicing correction of 46.5%,...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026